These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32343915)

  • 1.
    Lei T; Zhang L; Song Y; Wang B; Shen Y; Zhang N; Yang M
    DNA Cell Biol; 2020 Jul; 39(7):1111-1118. PubMed ID: 32343915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DACT2 modulated by TFAP2A-mediated allelic transcription promotes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
    Zhang N; Li Y; Xie M; Song Y; Liu J; Lei T; Shen Y; Yu J; Yang M
    Biochem Pharmacol; 2020 Feb; 172():113772. PubMed ID: 31866302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs.
    Zhang N; Li Y; Zheng Y; Zhang L; Pan Y; Yu J; Yang M
    Lab Invest; 2019 Apr; 99(4):568-576. PubMed ID: 30552364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogene HSPH1 modulated by the rs2280059 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
    Li Y; Zhang N; Zhang L; Song Y; Liu J; Yu J; Yang M
    Carcinogenesis; 2020 Sep; 41(9):1195-1202. PubMed ID: 32815538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RNA editing enzyme ADAR modulated by the rs1127317 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
    Hua H; Zeng J; Xing H; He Y; Han L; Zhang N; Yang M
    Life Sci; 2022 May; 296():120408. PubMed ID: 35202641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
    Wu DW; Wang YC; Wang L; Chen CY; Lee H
    Theranostics; 2018; 8(5):1256-1269. PubMed ID: 29507618
    [No Abstract]   [Full Text] [Related]  

  • 7. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
    Kawana S; Saito R; Miki Y; Kimura Y; Abe J; Sato I; Endo M; Sugawara S; Sasano H
    Cancer Med; 2021 Jan; 10(2):718-727. PubMed ID: 33305905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
    DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance.
    Dai C; Liu B; Li S; Hong Y; Si J; Xiong Y; Wu N; Ma Y
    Technol Cancer Res Treat; 2021; 20():15330338211056809. PubMed ID: 34825849
    [No Abstract]   [Full Text] [Related]  

  • 13. Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation.
    Wang YJ; Wang QW; Yu DH; Song CK; Guo ZX; Liu XP; Chen C; Yao J; Wang AF; Hu WD
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3245-3254. PubMed ID: 34255150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOTCH3 Overexpression and Posttranscriptional Regulation by miR-150 Were Associated With EGFR-TKI Resistance in Lung Adenocarcinoma.
    Zhang Y; Chen B; Wang Y; Zhao Q; Wu W; Zhang P; Miao L; Sun S
    Oncol Res; 2019 Jul; 27(7):751-761. PubMed ID: 30732676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
    Ma G; Zhu J; Liu F; Yang Y
    DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
    Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
    J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mPRα mediates P4/Org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway.
    Lu X; Guan A; Chen X; Xiao J; Xie M; Yang B; He S; You S; Li W; Chen Q
    Mol Carcinog; 2020 Feb; 59(2):179-192. PubMed ID: 31777985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
    Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
    Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world utilization of EGFR TKIs and prognostic factors for survival in NSCLC during 2010-2016 in Sweden: A nationwide observational study.
    Bergqvist M; Christensen HN; Wiklund F; Bergström S
    Int J Cancer; 2020 May; 146(9):2510-2517. PubMed ID: 31350754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.